Citi Starts Mirum Pharamceuticals (MIRM) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Price: $80.39 -3.26%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Citi analyst David Lebowitz initiates coverage on Mirum Pharamceuticals (NASDAQ: MIRM) with a Buy rating and a price target of $38.00.
For an analyst ratings summary and ratings history on Mirum Pharamceuticals click here. For more ratings news on Mirum Pharamceuticals click here.
Shares of Mirum Pharamceuticals closed at $24.98 yesterday.
You May Also Be Interested In
- Mirum Pharmaceuticals (MIRM) PT Raised to $145 at TD Cowen
- Raymond James Starts Benitec BioPharma (BNTC) at Outperform
- Citi Starts Japan Tobacco Inc. (2914:JP) (JAPAY) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
